Share on StockTwits

Equities research analysts at Credit Suisse initiated coverage on shares of Vital Therapies (NYSE:VTL) in a research note issued to investors on Monday, reports. The firm set an “outperform” rating and a $16.00 price target on the stock. Credit Suisse’s price objective suggests a potential upside of 29.24% from the company’s current price.

The analysts wrote, “VTL is developing a cell-based therapy for the treatment of alcohol-induced acute liver de-compensation (AILD). VTL’s extracorporeal liver assist device (ELAD) uses immortalized human liver cancer cells housed in a machine located outside the body to take over a portion of the liver’s workload which allows the liver to regenerate. “Current standard of care for targeted AILD patients carries a 50% mortality rate. The ELAD has shown a numerical 20% (not statistically significant) mortality benefit vs. standard of care in small phase 2 data sets.”

Vital Therapies (NYSE:VTL) opened at 12.38 on Monday. Vital Therapies has a 52-week low of $10.66 and a 52-week high of $13.00. The stock’s 50-day moving average is $12.30 and its 200-day moving average is $12.30. The company’s market cap is $261.4 million.

Vital Therapies, Inc is a biotherapeutic company. The Company focused on developing a cell-based therapy targeting the treatment of all forms of acute liver failure.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.